%0 Journal Article
%A Serrano-Conde, Esther
%A Leyva, Alba
%A Fuentes, Ana
%A de Salazar, Adolfo
%A Chueca, Natalia
%A Perez-Castro, Sonia
%A Regueiro, Benito
%A Rojas, Almudena
%A Mendoza, Joaquin
%A Rojas, Jose
%A Garcia, Federico
%T In vitro neutralizing activity of BNT162b2 mRNA-induced antibodies against full B.1.351 SARS-CoV-2 variant.
%D 2021
%U http://hdl.handle.net/10668/20020
%X SARS-CoV-2 variation represents a serious challenge to current COVID-19 vaccines. Recent reports suggest that B.1.351 and other variants may escape the neutralization activity of the antibodies generated by current vaccines. Ninety-nine healthcare workers undertaking BNT162b2 mRNA vaccination were sampled at baseline, on the day of the second dose, and 14 days after the latter. Neutralization activity against SARS-CoV-2 B.1, B.1.1.7 and B.1.351 was investigated using a Vero-E6 model. Eleven of the study participants had prior infection with SARS-CoV-2. Neutralization titers against the B.1 and the B.1.1.7 variants were not statistically different and were significantly higher than titers against the B.1.351 variant across pre-exposed and non-pre-exposed vaccinated individuals (p 1/80 after a single dose, while only 11% of non-exposed vaccinated individuals had titers >1/80. BNT162b2 mRNA-induced antibodies show a lower in vitro neutralizing activity against B.1.351 variant compared to neutralization against B.1.1.7 or B.1 variants. Interestingly, for individuals pre-exposed to SARS-CoV-2, one dose of BNT162b2 mRNA may be adequate to produce neutralizing antibodies against B.1.1.7 and B.1, while two doses of BNT162b2 mRNA provide optimal neutralizing antibody response against B.1.351 too.
%K B.1
%K B.1.1.7
%K B.1.351
%K BNT162b2 mRNA
%K SARS-CoV-2
%K neutralization
%K variants
%~